Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

NCT02320292 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

20

Enrollment

OTHER

Sponsor class

Stopped drug supply issues

Conditions

Ann Arbor Stage I Grade 1 Follicular Lymphoma
Ann Arbor Stage I Grade 2 Follicular Lymphoma
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma
Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma
Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma
Ann Arbor Stage III Grade 1 Follicular Lymphoma
Ann Arbor Stage III Grade 2 Follicular Lymphoma
Ann Arbor Stage IV Grade 1 Follicular Lymphoma
Ann Arbor Stage IV Grade 2 Follicular Lymphoma

Interventions

OTHER: Quality-of-Life Assessment
BIOLOGICAL: Rituximab
RADIATION: Yttrium Y-90 Ibritumomab Tiuxetan

Sponsor

Mayo Clinic